Rigel Pharmaceuticals Company Profile (NASDAQ:RIGL)

About Rigel Pharmaceuticals

Rigel Pharmaceuticals logoRigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company's clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura (ITP); a Phase II clinical trial for autoimmune hemolytic anemia (AIHA), and a Phase II clinical trial for IgA nephropathy (IgAN). It has approximately two oncology product candidates in Phase I development. The Company is also engaged in conducting research in the disease areas of inflammation/immunology, and muscle wasting/muscle endurance, among others. Its product pipeline includes R348, which is a topical ophthalmic Janus kinase (JAK)/SYK inhibitor. The R348 product candidate is in Phase II clinical trials for the treatment of dry eye in patients with ocular graft-versus-host disease (GvHD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: RIGL
  • CUSIP: 76655960
Key Metrics:
  • Previous Close: $3.70
  • 50 Day Moving Average: $3.17
  • 200 Day Moving Average: $2.60
  • 52-Week Range: $1.88 - $4.06
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.69
  • P/E Growth: -0.07
  • Market Cap: $349.98M
  • Outstanding Shares: 94,589,000
  • Beta: 1.16
Profitability:
  • Net Margins: -143.24%
  • Return on Equity: -59.78%
  • Return on Assets: -42.09%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 4.40%
  • Quick Ratio: 4.40%
Additional Links:
Companies Related to Rigel Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Rigel Pharmaceuticals (NASDAQ:RIGL) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.60 (105.41% upside)

Analysts' Ratings History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Show:
DateFirmActionRatingPrice TargetDetails
9/16/2016Jefferies GroupReiterated RatingBuy$8.50 -> $9.00View Rating Details
9/15/2016HC WainwrightReiterated RatingBuyView Rating Details
9/15/2016Piper Jaffray Cos.Set Price TargetBuy$11.00View Rating Details
8/30/2016BMO Capital MarketsBoost Price TargetOutperform$4.00 -> $6.00View Rating Details
8/3/2016JPMorgan Chase & Co.Reiterated RatingBuy$5.00View Rating Details
4/23/2016Credit Suisse Group AGUpgradeBuyView Rating Details
2/23/2015Wells Fargo & Co.Reiterated RatingHoldView Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Rigel Pharmaceuticals (NASDAQ:RIGL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016        
8/2/2016Q216($0.20)($0.15)$3.75 million$8.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.19)($0.19)$4.00 million$5.03 millionViewListenView Earnings Details
3/8/2016Q415($0.14)($0.14)$8.90 million$8.50 millionViewListenView Earnings Details
11/3/2015Q315($0.17)($0.08)$5.00 million$12.90 millionViewListenView Earnings Details
8/4/2015Q215($0.22)($0.16)$2.67 million$5.18 millionViewListenView Earnings Details
5/7/2015Q414($0.18)($0.21)$16.00 million$2.18 millionViewListenView Earnings Details
3/3/2015Q4($0.27)($0.25)$2.50 million$8.25 millionViewN/AView Earnings Details
11/4/2014Q314($0.27)($0.24)ViewN/AView Earnings Details
8/5/2014Q214($0.25)($0.29)$1.05 millionViewN/AView Earnings Details
5/7/2014Q114($0.25)($0.25)$0.43 millionViewN/AView Earnings Details
3/4/2014Q4 13($0.25)($0.19)$5.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.29)($0.27)$260.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.30)($0.26)$0.53 million$1.40 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.30)($0.29)$1.73 millionViewN/AView Earnings Details
3/5/2013Q4 2012($0.32)($0.30)ViewN/AView Earnings Details
11/6/2012Q312($0.38)($0.36)$0.84 millionViewN/AView Earnings Details
8/7/2012($0.34)($0.35)ViewN/AView Earnings Details
5/1/2012($0.33)($0.32)ViewN/AView Earnings Details
3/6/2012($0.28)($0.36)ViewN/AView Earnings Details
11/1/2011($0.28)($0.25)ViewN/AView Earnings Details
8/2/2011($0.36)($0.37)ViewN/AView Earnings Details
5/3/2011($0.36)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Rigel Pharmaceuticals (NASDAQ:RIGL)
Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-0.65 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.17)($0.17)($0.17)
Q2 20161($0.18)($0.18)($0.18)
Q3 20161($0.17)($0.17)($0.17)
Q4 20161$0.41$0.41$0.41
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Rigel Pharmaceuticals (NASDAQ:RIGL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Rigel Pharmaceuticals (NASDAQ:RIGL)
Insider Ownership Percentage: 7.07%
Institutional Ownership Percentage: 88.50%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/30/2016Donald G PayanEVPSell5,303$4.00$21,212.00View SEC Filing  
4/1/2015Donald G PayanEVPSell10,000$3.75$37,500.00View SEC Filing  
12/18/2014Dolly VanceEVPSell1,000$2.22$2,220.00View SEC Filing  
9/3/2014Donald G PayanEVPSell20,000$2.56$51,200.00View SEC Filing  
11/19/2013Bvf Partners P/Ilmajor shareholderSell484,622$2.64$1,279,402.08View SEC Filing  
6/7/2013Bvf Partners L P/IlMajor ShareholderBuy32,700$3.47$113,469.00View SEC Filing  
9/13/2012Dolly VanceEVPSell4,151$10.43$43,294.93View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Rigel Pharmaceuticals (NASDAQ:RIGL)
DateHeadline
News IconEarnings Take Center Stage; Analysts Weighing in on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Frisco Fastball (NASDAQ:RIGL)
friscofastball.com - September 25 at 6:16 PM
News IconInteresting RIGL Put And Call Options For November 18th (NASDAQ:RIGL)
www.stockoptionschannel.com - September 20 at 12:20 PM
4-traders.com logoRigel Pharmaceuticals : Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP (NASDAQ:RIGL)
www.4-traders.com - September 17 at 6:32 PM
News IconLong term Growth Analysis ofRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Newburgh Press (NASDAQ:RIGL)
newburghpress.com - September 16 at 6:49 PM
4-traders.com logoRigel Pharmaceuticals : Restructures to Focus on Fostamatinib Commercialization (NASDAQ:RIGL)
www.4-traders.com - September 16 at 10:37 AM
seekingalpha.com logoRigel Pharma cuts 38% of workforce as its transitions to commercializing lead product candidate fostamatinib (NASDAQ:RIGL)
seekingalpha.com - September 16 at 10:37 AM
bizjournals.com logoWhy this Peninsula biotech's layoffs aren't necessarily a bad thing (except for the 46 people losing their jobs) (NASDAQ:RIGL)
feeds.bizjournals.com - September 16 at 10:35 AM
marketwatch.com logoRigel Pharmaceuticals cuts 38% of workforce to refocus on fostamatinib - MarketWatch (NASDAQ:RIGL)
www.marketwatch.com - September 15 at 7:07 PM
smarteranalyst.com logoStock Update (NASDAQ:RIGL): Rigel Pharmaceuticals, Inc. Restructures to Focus on Fostamatinib Commercialization - Smarter Analyst (NASDAQ:RIGL)
www.smarteranalyst.com - September 15 at 10:38 AM
marketwatch.com logoRigel Pharmaceuticals cuts 38% of workforce to refocus on fostamatinib (NASDAQ:RIGL)
www.marketwatch.com - September 15 at 10:38 AM
publicnow.com logoRigel Restructures to Focus on Fostamatinib Commercialization (NASDAQ:RIGL)
www.publicnow.com - September 15 at 10:38 AM
biz.yahoo.com logoRIGEL PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors (NASDAQ:RIGL)
biz.yahoo.com - September 15 at 10:38 AM
fool.com logoWhy Rigel Pharmaceuticals' Stock Soared in August (NASDAQ:RIGL)
www.fool.com - September 14 at 9:50 AM
News IconStock Gapping Down Before the Bell: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Post News (NASDAQ:RIGL)
www.kentuckypostnews.com - September 7 at 7:11 PM
News IconThe Statistics Don't Lie: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Earnings Preview - The Voice Registrar (NASDAQ:RIGL)
voiceregistrar.com - September 7 at 7:11 PM
rttnews.com logoRigel Pharmaceuticals Inc. (RIGL) Soared To A New High On Phase 3 Study Results (NASDAQ:RIGL)
www.rttnews.com - September 1 at 7:00 PM
finance.yahoo.com logoBMO Thinks Rigel's Fostamatinib Market Opportunity Will Be Further Validated (NASDAQ:RIGL)
finance.yahoo.com - September 1 at 7:00 PM
benzinga.com logo7 Biggest Price Target Changes For Thursday - Benzinga (NASDAQ:RIGL)
www.benzinga.com - September 1 at 10:12 AM
schaeffersresearch.com logoAnalyst Upgrades: Sirius XM Holdings Inc., Rigel Pharmaceuticals, Inc., and Veeva Systems Inc - Schaeffers Research (blog) (NASDAQ:RIGL)
www.schaeffersresearch.com - August 31 at 12:18 PM
capitalcube.com logoETF’s with exposure to Rigel Pharmaceuticals, Inc. : August 31, 2016 (NASDAQ:RIGL)
www.capitalcube.com - August 31 at 12:18 PM
thestreet.com logoRigel Pharma (RIGL) Stock Jumps on Study Results, Piper Jaffray Ups Price Target (NASDAQ:RIGL)
www.thestreet.com - August 30 at 6:58 PM
News IconWhat The Latest Data Means For Rigel Pharmaceuticals, Inc. (RIGL) (NASDAQ:RIGL)
feedproxy.google.com - August 30 at 5:00 PM
investorplace.com logoRigel Pharmaceuticals, Inc. (RIGL) Up Nearly 50% on Study Results, Price Target Increase (NASDAQ:RIGL)
investorplace.com - August 30 at 1:51 PM
feeds.benzinga.com logo15 Stocks Moving In Tuesday's Pre-Market Session (NASDAQ:RIGL)
feeds.benzinga.com - August 30 at 10:24 AM
streetinsider.com logoRigel Pharma (RIGL) Oral Spleen Tyrosine Kinase (SYK) Inhibitor ... - StreetInsider.com (NASDAQ:RIGL)
www.streetinsider.com - August 30 at 10:21 AM
biz.yahoo.com logoRIGEL PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi (NASDAQ:RIGL)
biz.yahoo.com - August 30 at 10:21 AM
publicnow.com logoRigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP (NASDAQ:RIGL)
www.publicnow.com - August 30 at 10:21 AM
thestreet.com logoRigel Pharma Claims Late-Stage Study Win for Blood Platelet Drug (NASDAQ:RIGL)
www.thestreet.com - August 30 at 10:21 AM
biz.yahoo.com logoRigel Pharmaceuticals Inc Conference Call to Discuss Its First of Two FIT Phase 3 Results of Fostamatinib scheduled for 8:00 am ET today (NASDAQ:RIGL)
biz.yahoo.com - August 30 at 10:21 AM
247wallst.com logoWhy Rigel Pharma Is Making a Run (NASDAQ:RIGL)
247wallst.com - August 30 at 10:21 AM
feeds.reuters.com logoUPDATE 1-Rigel's bleeding disorder drug clears first of two key trials (NASDAQ:RIGL)
feeds.reuters.com - August 30 at 9:20 AM
feeds.benzinga.com logoRigel's Oral Spleen Tyrosine Kinase Inhibitor Meets Primary Endpoint In Final Stage Trial In Chronic ITP (NASDAQ:RIGL)
feeds.benzinga.com - August 30 at 8:38 AM
feeds.reuters.com logoRigel's bleeding disorder drug clears first of two key trials (NASDAQ:RIGL)
feeds.reuters.com - August 30 at 7:51 AM
finance.yahoo.com logo5:36 pm Rigel Pharma confirms it will announce results of the first of two FIT Phase 3 studies of fostamatinib for patients with immune thrombocytopenia at 7 AM tomorrow morning (NASDAQ:RIGL)
finance.yahoo.com - August 29 at 6:54 PM
publicnow.com logoRigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016 (NASDAQ:RIGL)
www.publicnow.com - August 29 at 6:54 PM
News IconRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Upcoming Earnings: What matter for investors? - The Voice Registrar (NASDAQ:RIGL)
voiceregistrar.com - August 27 at 6:20 PM
News IconPenny Stock Under the Microscope: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Duncan Research (NASDAQ:RIGL)
www.duncanindependent.com - August 25 at 12:12 PM
marketexclusive.com logoWhat We’re Looking For From The Upcoming Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Data (NASDAQ:RIGL)
marketexclusive.com - August 23 at 11:38 AM
insidermonkey.com logoWhat We’re Looking For From The Upcoming Rigel Pharmaceuticals, Inc. (RIGL) Data (NASDAQ:RIGL)
www.insidermonkey.com - August 23 at 11:38 AM
investornewswire.com logoWill Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Hit $10 Price Target? - Investor Newswire (NASDAQ:RIGL)
www.investornewswire.com - August 20 at 6:46 PM
News IconPenny Stock Alert - Update & Review on This Stock: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Duncan Research (NASDAQ:RIGL)
www.duncanindependent.com - August 19 at 6:59 PM
capitalcube.com logoETF’s with exposure to Rigel Pharmaceuticals, Inc. : August 19, 2016 (NASDAQ:RIGL)
www.capitalcube.com - August 19 at 6:59 PM
News IconRigel Pharmaceuticals, Inc.'s (RIGL): Trader's Buzzer - Hot Stocks Point (NASDAQ:RIGL)
www.hotstockspoint.com - August 19 at 10:04 AM
News IconTaking A Closer Look at Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Duncan Research (NASDAQ:RIGL)
www.duncanindependent.com - August 17 at 7:31 PM
News IconTop Earnings to Watch for: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - The Voice Registrar (NASDAQ:RIGL)
voiceregistrar.com - August 17 at 7:31 PM
seekingalpha.com logoBinary event looming for Rigel Pharma investors - Seeking Alpha (NASDAQ:RIGL)
seekingalpha.com - August 17 at 7:31 PM
News IconA Closer Look at Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Duncan Research (NASDAQ:RIGL)
www.duncanindependent.com - August 16 at 7:15 PM
News IconNoteworthy Thursday Option Activity: RIGL, X, DIS (NASDAQ:RIGL)
www.stockoptionschannel.com - August 11 at 7:38 PM
finance.yahoo.com logoRIGEL PHARMACEUTICALS INC Financials (NASDAQ:RIGL)
finance.yahoo.com - August 9 at 7:25 PM
capitalcube.com logoETF’s with exposure to Rigel Pharmaceuticals, Inc. : August 8, 2016 (NASDAQ:RIGL)
www.capitalcube.com - August 8 at 7:22 PM

Social

Rigel Pharmaceuticals (NASDAQ:RIGL) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff